Medscape covers a comparison in a diverse group of patients with obesity where bariatric surgery outperformed tirzepatide. Full results are at the link.
Recap by typeshit. Full story at Medscape.
The candidate blocks a signal behind appetite loss and high energy burn in cancer cachexia, where patients waste away even while eating.
The new preprint looks at whether symptom relief people report on GLP-1 medications comes from weight loss alone or something else.
Lilly says participants lost 44 to 47 pounds versus about 21 on Ozempic, with bigger A1C drops. It plans to file for approval in 2027.
Lilly reports people on retatrutide lost 44 to 47 pounds over 80 weeks versus about 21 on Ozempic. It plans to file for approval in 2027.
Healio
Published in NEJM, the 80-week trial of 2,339 adults with obesity saw weight drop up to 25% on the 12 mg dose, with researchers reporting pain cut by as much as 61.6%.
Strong sales of its obesity injections pushed Lilly past profit expectations, and the drugmaker raised its full-year outlook, Reuters reports.
Loading…